Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 14/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742215 | 0.81 | PDPK1 (1.00) | PDPK1 | |
| SCHEMBL4929414 | 0.80 | PDPK1 (0.58) | PDPK1FLT1KDR | |
| SCHEMBL4747109 | 0.79 | PDPK1 (0.70) | PDPK1POLBTLR7 | |
| SCHEMBL4745738 | 0.78 | PDPK1 (0.61) | PDPK1TLR7 | |
| SCHEMBL4747108 | 0.78 | PDPK1 (0.58) | PDPK1LMNAGLAPOLBGAA | |
| SCHEMBL4747115 | 0.77 | PDPK1 (0.55) | PDPK1POLBKMT2AFLT1 | |
| SCHEMBL4741555 | 0.77 | PDPK1 (0.73) | PDPK1 | |
| SCHEMBL4747760 | 0.77 | PDPK1 (0.56) | PDPK1LMNATLR7 | |
| SCHEMBL4747105 | 0.77 | PDPK1 (0.59) | PDPK1KDR | |
| SCHEMBL4744912 | 0.76 | PDPK1 (0.82) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | claimed |
| WO-2008109599-A1 | PYRIMIDO [5,4-C] QUINOLINE-2, 4-DIAMINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2008-09-12 | — | — | WO | claimed |
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008109599-A1 | PYRIMIDO [5,4-C] QUINOLINE-2, 4-DIAMINE DERIVATIVES AND METHODS OF USE THEREOF | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234300-A1 | Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof | DCK, PDK4, PDK2 | PDPK1 6/4885LMNA 3144/4885GLA 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.